Sellas Life Sciences has reported the multicentre Phase IIa trial data of a highly selective cyclin-dependent kinase 9 (CDK9) ...

These investigators assessed the potential benefit of a high-risk signature to evaluate the molecular drivers of primary treatment resistance in patients with DLBCL. Share on Facebook. Opens in a ...

and having liver metastases increases the likelihood of a poor outcome in patients with primary pulmonary diffuse large B-cell lymphoma (PP-DLBCL), according to new research on prognostic factors ...

Epcoritamab combined with GemOx shows deep, durable responses in transplant-ineligible relapsed/refractory diffuse large ...

MSD began worldwide recruitment for the trial and subjects are currently being enrolled. In the randomised trial, the ...

UK health technology assessor the National Institute for Health and Care Excellence (NICE) has issued Final Draft Guidance ...

The addition of epcoritamab-bysp to standard chemotherapy significantly improved response and survival for patients with ...

It will measure progression-free survival (PFS) as its primary endpoint ... with zilovertamab vedotin in patients with diffuse large B-cell lymphoma, compared to the current standard treatment.” ...

Approval of Adcetris provides a new treatment option for patients with relapsed or refractory large b-cell lymphoma who are ...

Matthew S. McKinney, MD, reflects on his first experience of treating a patient with diffuse large B-cell lymphoma (DLBCL) as a new attending at Duke University. The patient, a woman with multiple ...